What is Lurasidone Market?
Lurasidone is a novel antipsychotic agent used to treat certain mental/mood disorders (such as schizophrenia, depression associated with bipolar disorder). It helps to think more clearly, feel less nervous and take part in everyday life. It also helps to improve sleep, appetite, mood and energy level. Lurasidone works by helping to restore the balance of certain natural substances in the brain.
The market study is being classified by Type (20mg/tablet, 40mg/tablet, 60mg/tablet, 80mg/tablet and 120mg/tablet) and major geographies with country level break-up.
Sunovion Pharmaceuticals Inc. (United States), Angelini Holding S.p.A. (Italy), Sumitomo Dainippon Pharma Co., Ltd. (Japan), Sigma-Aldrich (United States), Lupin Limited (India), Bushu Pharmaceutical, LTD. (Japan), Zhejiang Hisun Pharmaceutical Co., Ltd. (China), LGM Pharma (United States) and Healthcare Pharmaceuticals Limited (Bangladesh) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Square Pharmaceuticals Ltd. (Bangladesh), Incepta Pharmaceuticals Ltd. (Bangladesh) and Maps Laboratories PVT. LTD. (India).
The companies are exploring the market by adopting expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain a competitive advantage through combined collaborations. Research Analyst at AMA predicts that Global Players will contribute to the maximum growth of Global Lurasidone market throughout the predicted period.
Analyst at AMA have segmented the market study of Global Lurasidone market by Type, Application and Region.
On the basis of geography, the market of Lurasidone has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
- Increased Prevalence of Mental/Mood Disorders among People due to Hectic Lifestyle
- Rising Regulatory Approvals for Lurasidone
- Technological Advancements in the field of Medical Science
- Side Effects such as Serious Drop in Blood Pressure
- Growth in the Healthcare Industry
- Robust Increase in Distribution Channels
- Stringent Government Rules and Regulations
In September 2019, Sumitomo Dainippon Pharma Co., Ltd. has announced that Sumitomo Pharmaceuticals (Suzhou) Co., Ltd., its wholly-owned subsidiary in China, launched an atypical antipsychotic LATUDA (generic name: lurasidone hydrochloride) in China for the treatment of adult patients with schizophrenia.
Key Target AudienceLurasidone Manufacturers, Raw Material Suppliers, Distributors, Emerging Companies, Research Professionals and End-users
Customization in the Report Available:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase